Vardenafil (Levitra/Staxyn) and NSAIDs (Ibuprofen, Naproxen): Interaction Guide

Why This Combination Matters

Most men prescribed vardenafil for erectile dysfunction will reach for ibuprofen or naproxen at some point for headache, joint pain, or post-exercise soreness. The two drug classes are among the most widely used medications in the United States, which makes their overlap almost inevitable.

The interaction is pharmacodynamic, not pharmacokinetic. Vardenafil is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C9 [1]. Ibuprofen and naproxen are metabolized by CYP2C9 as well, but at therapeutic doses neither drug inhibits CYP3A4 to a clinically meaningful degree [2]. That means plasma levels of vardenafil do not rise when an NSAID is co-administered. The concern instead centers on three overlapping physiologic effects: blood-pressure lowering, platelet inhibition, and renal hemodynamic stress.

A 2018 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that PDE5 inhibitor use concurrent with NSAIDs was associated with a reporting odds ratio of 1.4 (95% CI 1.1 to 1.8) for bleeding events compared with PDE5 inhibitor use alone [3]. The signal was modest but consistent across all three major PDE5 inhibitors (sildenafil, tadalafil, vardenafil).

Blood-Pressure Effects: Additive but Usually Mild

Vardenafil lowers systolic blood pressure by an average of 5 to 6 mmHg and diastolic by 3 to 4 mmHg at peak plasma concentration (approximately 1 hour post-dose), according to the FDA-approved Levitra label [1]. NSAIDs, by contrast, can raise blood pressure in hypertensive patients by 2 to 5 mmHg through sodium retention and blunting of antihypertensive medications [4]. In normotensive men, however, ibuprofen and naproxen may produce a slight vasodilatory effect acutely.

The net result is context-dependent. A normotensive man who takes 400 mg ibuprofen for a headache and 10 mg vardenafil two hours later is unlikely to notice any hemodynamic shift. A man on triple antihypertensive therapy who uses naproxen 500 mg twice daily and adds vardenafil faces a more complex hemodynamic picture. The American Heart Association's 2017 hypertension guideline recommends limiting NSAID exposure in patients already on multiple blood-pressure agents [5]. Adding a PDE5 inhibitor to that regimen introduces one more variable.

Practical rule: check a standing and seated blood pressure before and after the first combined dose if the patient is on two or more antihypertensives.

GI and Bleeding Risk

NSAIDs inhibit cyclooxygenase-1 (COX-1), reducing thromboxane A2 synthesis and impairing platelet aggregation. This is well-characterized. Less widely appreciated is the effect of PDE5 inhibitors on platelet function. Vardenafil raises intracellular cyclic guanosine monophosphate (cGMP) in platelets, which inhibits the glycoprotein IIb/IIIa receptor and reduces platelet activation [6]. A 2005 in vitro study published in Thrombosis and Haemostasis demonstrated that sildenafil (pharmacologically analogous to vardenafil in this pathway) potentiated the antiplatelet effect of aspirin and other COX inhibitors by 30 to 40% in aggregometry assays [6].

No randomized trial has isolated the vardenafil-plus-NSAID pair for GI bleeding outcomes specifically. The evidence is extrapolated from the PDE5 inhibitor class and from the FAERS signal noted above [3]. A 2021 Danish cohort study of 42,558 men prescribed PDE5 inhibitors found a hazard ratio of 1.23 (95% CI 1.06 to 1.43) for upper GI bleeding in those concurrently dispensed an NSAID versus those who were not [7].

For a man with no history of peptic ulcer disease who takes occasional ibuprofen, the absolute added risk is small. For a man over 60 with prior GI bleeding or concurrent anticoagulant use, the combination deserves a gastroprotective strategy (proton pump inhibitor co-prescription, for instance) per the 2022 American College of Gastroenterology guideline on NSAID-associated GI risk [8].

Renal Considerations

NSAIDs reduce prostaglandin-mediated afferent arteriolar vasodilation in the kidney, which can lower glomerular filtration rate (GFR) by 10 to 20% during sustained use [9]. Vardenafil does not directly affect renal prostaglandins, but it does reduce systemic blood pressure, which can compound the renal perfusion drop in susceptible patients.

The populations at risk overlap: men over 65, patients with baseline eGFR <60 mL/min/1.73 m², and those on ACE inhibitors or ARBs. The so-called "triple whammy" (NSAID + ACE inhibitor/ARB + diuretic) is a recognized precipitant of acute kidney injury [10]. Adding vardenafil does not create a quadruple whammy per se, but the additional hemodynamic burden warrants caution. A reasonable monitoring approach is to check serum creatinine and potassium within 7 to 14 days of starting chronic NSAID therapy in any man who also uses vardenafil and an ACE inhibitor or ARB.

Short-term NSAID use (fewer than 5 days) with vardenafil poses minimal renal risk in men with normal kidney function.

Pharmacokinetic Details: Why No Dose Adjustment Is Needed

Vardenafil is a substrate of CYP3A4 (major) and CYP2C9 (minor). Its absorption is not affected by antacids, food fat content modestly delays Tmax, and the drug is 95% protein-bound [1]. Ibuprofen is metabolized by CYP2C9 and CYP2C8; naproxen is metabolized primarily by CYP2C9 and, to a lesser degree, CYP1A2 [2]. Neither ibuprofen nor naproxen inhibits or induces CYP3A4.

The protein-binding overlap (both drug classes are >95% albumin-bound) theoretically could displace one drug, raising free-fraction concentrations. In practice, displacement interactions rarely produce clinically significant effects because the increase in free drug is rapidly offset by increased hepatic clearance [11]. No published case report or pharmacokinetic study has documented a meaningful change in vardenafil exposure when co-administered with ibuprofen or naproxen.

Bottom line: no dose reduction of either drug is required on pharmacokinetic grounds.

Who Should Be More Careful

Not every man faces the same risk profile. The following subgroups warrant closer monitoring or an alternative analgesic strategy:

Men on anticoagulants or antiplatelet agents. Adding both vardenafil (which raises platelet cGMP) and an NSAID (which blocks COX-1) to warfarin or apixaban creates three simultaneous hits on hemostasis. The 2019 European Society of Cardiology position paper on antithrombotic management advises avoiding NSAIDs entirely in patients on oral anticoagulants when possible [12].

Men with CKD stage 3 or worse. Baseline GFR <60 mL/min/1.73 m² already limits renal reserve. NSAID-induced prostaglandin suppression on top of vardenafil-induced systemic vasodilation may trigger an acute-on-chronic GFR decline.

Men over 65. Age-related declines in hepatic CYP3A4 activity slow vardenafil clearance, producing higher peak concentrations. The Levitra label recommends a 5 mg starting dose in men 65 and older [1]. Higher vardenafil exposure amplifies the pharmacodynamic overlap with NSAIDs.

Men with a history of peptic ulcer or GI bleeding. The additive platelet-inhibitory effect of the combination raises rebleed probability. An alternative analgesic (acetaminophen, for example) eliminates this concern entirely.

Safer Alternatives for Pain Relief

Acetaminophen (paracetamol) has no antiplatelet activity, no effect on renal prostaglandins, and no interaction with CYP3A4 at standard doses of <3 g/day [13]. It is the preferred first-line analgesic for men taking vardenafil who need occasional pain relief.

Topical NSAIDs (diclofenac gel, for instance) deliver local anti-inflammatory concentrations with systemic NSAID levels roughly 5 to 10% of oral dosing, according to a Cochrane review of topical NSAID pharmacokinetics [14]. This substantially reduces the bleeding and renal concerns while preserving anti-inflammatory benefit for localized musculoskeletal pain.

If oral NSAID therapy is necessary (rheumatoid arthritis, acute gout), using the lowest effective dose for the shortest duration remains the standing FDA recommendation [15]. Naproxen may carry a slightly lower cardiovascular risk than ibuprofen based on the PRECISION trial (N=24,081), which found naproxen noninferior to celecoxib for major cardiovascular events [16].

Monitoring Recommendations

For men who will use both drugs repeatedly, a practical monitoring framework includes:

1. Baseline labs. CBC with platelet count, serum creatinine, eGFR, and potassium before starting chronic NSAID therapy.
2. Blood-pressure check. Seated and standing measurements after the first co-administration, especially if the patient takes antihypertensives.
3. Follow-up labs at 2 weeks. Repeat creatinine and potassium if the patient is on an ACE inhibitor, ARB, or diuretic.
4. GI symptom screening. Ask about epigastric pain, dark stools, or new reflux at each visit.
5. Annual reassessment. Review whether chronic NSAID use is still indicated; consider de-escalation to acetaminophen or topical NSAID.

What the FDA Labels Say

The Levitra (vardenafil) prescribing information lists alpha-blockers, nitrates, antiarrhythmics (Class IA and III), and strong CYP3A4 inhibitors as drugs requiring dose adjustment or avoidance [1]. NSAIDs are not mentioned. The ibuprofen OTC label warns about combination with anticoagulants, corticosteroids, and other NSAIDs, but does not reference PDE5 inhibitors [15]. The absence of a label warning does not mean zero interaction. It means the interaction has not reached the threshold of clinical significance that compels a boxed or bolded warning.

The Micromedex, Lexicomp, and Clinical Pharmacology DDI databases all classify the PDE5 inhibitor/NSAID combination as "minor" to "moderate" severity, with a recommendation to monitor rather than avoid [17].